Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Antithrombin deficiency

Kenneth A Bauer, MD
Section Editor
Lawrence LK Leung, MD
Deputy Editor
Jennifer S Tirnauer, MD


Deficiency of antithrombin (AT; antithrombin III) can be inherited or acquired. In some patients, AT deficiency can be associated with an increased risk of thromboembolism. The availability of plasma-derived AT concentrates and recombinant AT has made it possible to replace AT, but the appropriate clinical uses of these products remain unclear. This topic discusses the causes, evaluation, and management of inherited and acquired AT deficiencies.

Additional topic reviews discuss other inherited thrombophilias and their management.

Factor V Leiden mutation – (See "Factor V Leiden and activated protein C resistance".)

Prothrombin mutation – (See "Prothrombin G20210A mutation".)

Protein S deficiency – (See "Protein S deficiency".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jul 25, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010; 85:947.
  2. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76:651.
  3. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112:19.
  4. Loncar R, Kalina U, Stoldt V, et al. Antithrombin significantly influences platelet adhesion onto immobilized fibrinogen in an in-vitro system simulating low flow. Thromb J 2006; 4:19.
  5. Fitches AC, Appleby R, Lane DA, et al. Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood 1998; 92:4671.
  6. Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94:3388.
  7. McDonald MM, Hathaway WE, Reeve EB, Leonard BD. Biochemical and functional study of antithrombin III in newborn infants. Thromb Haemost 1982; 47:56.
  8. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165.
  9. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72:1651.
  10. Gader A, Bahakim H, Awadalla S, Malaika S. Ethnic variations in the haemostatic system: comparison between Arabs, Westerners (Europeans and Americans), Asians and Africans. Blood Coagul Fibrinolysis 1995; 6:537.
  11. Al-Mugeiren MM, Abdel Gader AG, Al-Meshari AA, et al. Normal levels of the natural anticoagulants (proteins C & S and antithrombin III) and the fibrinolytic factors (tPA and PAI) in Arab children. Ann Saudi Med 1996; 16:501.
  12. Kumar R, Chan AK, Dawson JE, et al. Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. Br J Haematol 2014; 166:130.
  13. https://www1.imperial.ac.uk/departmentofmedicine/divisions/experimentalmedicine/haematology/coag/antithrombin/.
  14. Ambruso DR, Leonard BD, Bies RD, et al. Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood 1982; 60:78.
  15. Bock SC, Harris JF, Schwartz CE, et al. Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet 1985; 37:32.
  16. Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988; 27:6171.
  17. Hultin MB, McKay J, Abildgaard U. Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost 1988; 59:468.
  18. Bock SC, Silberman JA, Wikoff W, et al. Identification of a threonine for alanine substitution at residue 404 of antithrombin III Oslo suggests integrity of the 404-407 region is important for maintaining normal plasma inhibitor levels. Thromb Haemost 1989; 62:494.
  19. Navarro-Fernández J, de la Morena-Barrio ME, Padilla J, et al. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb Haemost 2016; 116:146.
  20. Ambruso DR, Jacobson LJ, Hathaway WE. Inherited antithrombin III deficiency and cerebral thrombosis in a child. Pediatrics 1980; 65:125.
  21. Cosgriff TM, Bishop DT, Hershgold EJ, et al. Familial antithrombin III deficiency: its natural history, genetics, diagnosis and treatment. Medicine (Baltimore) 1983; 62:209.
  22. Sas G, Blaskó G, Bánhegyi D, et al. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32:105.
  23. Olds RJ, Lane DA, Caso R, et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood 1992; 79:1206.
  24. Manco-Johnson MJ. Neonatal antithrombin III deficiency. Am J Med 1989; 87:49S.
  25. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24:19.
  26. Damus PS, Wallace GA. Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy. Thromb Res 1975; 6:27.
  27. Raya-Sánchez JM, González-Reimers E, Rodríguez-Martín JM, et al. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998; 15:19.
  28. Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25:683.
  29. Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65:607.
  30. Chen TY, Huang CC, Tsao CJ. Hemostatic molecular markers in nephrotic syndrome. Am J Hematol 1993; 44:276.
  31. Alegre A, Vicente V, Gonzalez R, Alberca I. Effect of hemodialysis on protein C levels. Nephron 1987; 46:386.
  32. Lechner K, Kyrle PA. Antithrombin III concentrates--are they clinically useful? Thromb Haemost 1995; 73:340.
  33. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2:581.
  34. Weenink GH, Kahlé LH, Lamping RJ, et al. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand 1984; 63:57.
  35. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68:392.
  36. Panicucci F, Sagripanti A, Conte B, et al. Antithrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological condition. Haemostasis 1980; 9:297.
  37. Weenink GH, Treffers PE, Vijn P, et al. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984; 148:1092.
  38. Meade TW, Dyer S, Howarth DJ, et al. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990; 74:77.
  39. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemost 1992; 65:839.
  40. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87:106.
  41. Odegård OR, Abildgaard U. Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis 1978; 7:127.
  42. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.
  43. Limperger V, Franke A, Kenet G, et al. Clinical and laboratory characteristics of paediatric and adolescent index cases with venous thromboembolism and antithrombin deficiency. An observational multicentre cohort study. Thromb Haemost 2014; 112:478.
  44. Wells PS, Blajchman MA, Henderson P, et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol 1994; 45:321.
  45. Remak G, Hottenstein OD, Jacobson ED. Multifactorial mediation of post norepinephrine induced intestinal hyperemia. J Physiol Pharmacol 1994; 45:241.
  46. Meillón-García LA, Hernández-Zamora E, Montiel-Manzano G, et al. Anticoagulant proteins in a population of Mexican mestizo donors. Ann Vasc Surg 2015; 29:222.
  47. Tait RC, Walker ID, Davidson JF, et al. Antithrombin III activity in healthy blood donors: age and sex related changes and prevalence of asymptomatic deficiency. Br J Haematol 1990; 75:141.
  48. Candrina R, Goppini A, Salvi A, et al. Arterial thrombosis in antithrombin III deficiency. Clin Lab Haematol 1986; 8:267.
  49. Di Minno MN, Ambrosino P, Ageno W, et al. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2015; 135:923.
  50. Bucciarelli P, Rosendaal FR, Tripodi A, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999; 19:1026.
  51. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3:459.
  52. Demers C, Ginsberg JS, Hirsh J, et al. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116:754.
  53. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. In: Clinics in Haematology, Prentice CR (Ed), Saunders, London 1981. Vol 10, p.369.
  54. Maung R, Kelly JK, Schneider MP, Poon MC. Mesenteric venous thrombosis due to antithrombin III deficiency. Arch Pathol Lab Med 1988; 112:37.
  55. Wilson C, Walker ID, Davidson JF, Imrie CW. Mesenteric venous thrombosis and antithrombin III deficiency. J Clin Pathol 1987; 40:906.
  56. Bertram B, Remky A, Arend O, et al. Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Ger J Ophthalmol 1995; 4:332.
  57. Ellis D. Recurrent renal vein thrombosis and renal failure associated with antithrombin-III deficiency. Pediatr Nephrol 1992; 6:131.
  58. Daif A, Awada A, al-Rajeh S, et al. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke 1995; 26:1193.
  59. Das M, Carroll SF. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome. Surgery 1985; 97:242.
  60. Walker ID. Congenital thrombophilia. Baillieres Clin Obstet Gynaecol 1997; 11:431.
  61. Rhéaume M, Weber F, Durand M, Mahone M. Pregnancy-Related Venous Thromboembolism Risk in Asymptomatic Women With Antithrombin Deficiency: A Systematic Review. Obstet Gynecol 2016; 127:649.
  62. Conard J, Horellou MH, Van Dreden P, et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63:319.
  63. James AH, Konkle BA, Bauer KA. Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. Int J Womens Health 2013; 5:233.
  64. Picard V, Dautzenberg MD, Villoutreix BO, et al. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood 2003; 102:919.
  65. Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood 1991; 78:2299.
  66. Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130:107.
  67. Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102:276.
  68. Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg 2008; 85:2153.
  69. Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68:589.
  70. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257:2162.
  71. Wunderwald P, Schrenk WJ, Port H. Antithrombin BM from human plasma: an antithrombin binding moderately to heparin. Thromb Res 1982; 25:177.
  72. Demers C, Henderson P, Blajchman MA, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69:231.
  73. Corral J, Hernandez-Espinosa D, Soria JM, et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109:4258.
  74. Michiels JJ, Hamulyák K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 1998; 24:309.
  75. Marciniak E, Farley CH, DeSimone PA. Familial thrombosis due to antithrombin 3 deficiency. Blood 1974; 43:219.
  76. Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med 1989; 87:53S.
  77. Menache D, O'Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990; 75:33.
  78. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM134045.pdf.
  79. Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43:390.
  80. Paidas MJ, Forsyth C, Quéré I, et al. Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Blood Coagul Fibrinolysis 2014; 25:444.
  81. Ryerson LM, Bruce AK, Lequier L, et al. Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy. ASAIO J 2014; 60:559.
  82. Kozul C, Newall F, Monagle P, et al. A clinical audit of antithrombin concentrate use in a tertiary paediatric centre. J Paediatr Child Health 2012; 48:681.
  83. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70:873.
  84. Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998; 38:481.
  85. Skelley JW, White CW, Thomason AR. The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis 2017; 43:24.
  86. Tengborn L, Bergqvist D. Surgery in patients with congenital antithrombin III deficiency. Acta Chir Scand 1988; 154:179.
  87. Nowak-Göttl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009; 22:103.
  88. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90:235.
  89. Korte W, Greiner J. PARKAA paves the way. Thromb Haemost 2003; 90:163.
  90. Astwood E, Vora A. Personal practice: how we manage the risk of bleeding and thrombosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol 2011; 152:505.
  91. Meister B, Kropshofer G, Klein-Franke A, et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 50:298.
  92. Abbott LS, Deevska M, Fernandez CV, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009; 114:5146.
  93. Nowak-Göttl U, Rath B, Binder M, et al. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica 1995; 80:451.
  94. Halton JM, Mitchell LG, Vegh P, et al. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol 1994; 47:157.
  95. Wong TE, Huang YS, Weiser J, et al. Antithrombin concentrate use in children: a multicenter cohort study. J Pediatr 2013; 163:1329.
  96. Niimi KS, Fanning JJ. Initial experience with recombinant antithrombin to treat antithrombin deficiency in patients on extracorporeal membrane oxygenation. J Extra Corpor Technol 2014; 46:84.
  97. Hursting MJ, Murray PT. Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron Clin Pract 2008; 109:c80.
  98. Ota K, Akizawa T, Hirasawa Y, et al. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003; 18:1623.
  99. Unver S, Atasoyu EM, Evrenkaya TR, et al. Vena cava superior syndrome developing in a dialysis patient with antithrombin III deficiency following temporary catheterization. Clin Nephrol 2006; 65:71.
  100. Hara T, Naito K. Inherited antithrombin deficiency and end stage renal disease. Med Sci Monit 2005; 11:RA346.
  101. Nicastro MA, Plana JL, Heller MV, et al. Antithrombin III supplementation allowed haemodialysis without heparin after kidney transplantation. Nephrol Dial Transplant 1993; 8:1281.
  102. Rosendaal FR, Heijboer H, Briët E, et al. Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet 1991; 337:260.
  103. van Boven HH, Vandenbroucke JP, Westendorp RG, Rosendaal FR. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997; 77:452.